We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

14 hedge funds and large institutions have $70.6M invested in Ambrx Biopharma Inc in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

13% less funds holding

Funds holding: 16 → 14 (-2)

54% less capital invested

Capital invested by funds: $152M → $70.6M (-$81.4M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
14
Holders Change
-2
Holders Change %
-12.5%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
5
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
+$2.22M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$530K
3
Renaissance Technologies
Renaissance Technologies
New York
+$55.2K
4
Millennium Management
Millennium Management
New York
+$30.7K
5
Bank of America
Bank of America
North Carolina
+$563

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$959K
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$152K
3
CCM
CAAS Capital Management
New York
-$118K
4
BlackRock
BlackRock
New York
-$92.1K
5
MIFH
Migdal Insurance & Financial Holdings
Israel
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$15.8M -$152K -29,666 -0.8%
BlackRock
2
BlackRock
New York
$11.7M -$92.1K -18,000 -0.6%
CAM
3
Cormorant Asset Management
Massachusetts
$10.2M – – –
AG
4
Artal Group
Luxembourg
$8.87M – – –
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$8.35M +$530K +103,591 +5%
FI
6
Fosun International
China
$7.96M – – –
SCM
7
Suvretta Capital Management
New York
$6.15M +$2.22M +434,097 +41%
OCA
8
Octagon Capital Advisors
New York
$616K -$959K -187,468 -56%
Millennium Management
9
Millennium Management
New York
$430K +$30.7K +6,010 +6%
Norges Bank
10
Norges Bank
Norway
$288K – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$93K +$55.2K +10,800 +92%
Tudor Investment Corp
12
Tudor Investment Corp
Connecticut
$83K – – –
Morgan Stanley
13
Morgan Stanley
New York
$12K – – –
Bank of America
14
Bank of America
North Carolina
$1K +$563 +110 +84%
CCM
15
CAAS Capital Management
New York
– -$118K -13,068 Closed
MIFH
16
Migdal Insurance & Financial Holdings
Israel
– -$1K -124 Closed

AMAM Hedge Fund Activity: Q1 2022 in Review

14 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q1 2022, worth a combined $70.6M — down 54% from $152M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of AMAM and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was Suvretta Capital Management, adding an estimated $2.22M. The largest seller was Octagon Capital Advisors, cutting an estimated $959K.

  • 14 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q1 2022, down from 16 in Q4 2021.
  • Funds reported $70.6M of Ambrx Biopharma Inc stock for Q1 2022, down 54% quarter-over-quarter.
  • 0 funds opened new Ambrx Biopharma Inc positions in Q1 2022 and 2 closed out, a net change of -2 holders.
  • The largest Ambrx Biopharma Inc buyer in Q1 2022 was Suvretta Capital Management, an estimated $2.22M added.
  • The largest Ambrx Biopharma Inc seller in Q1 2022 was Octagon Capital Advisors, an estimated $959K sold.

Based on aggregated 13F filings for Q1 2022.